Maze Therapeutics (NASDAQ:MAZE) Shares Climb 4.7% - Still a Buy?

Key Points

• Maze Therapeutics shares rose 4.7% to about $28.38, although trading volume was 73% below the average session level.
• Analyst sentiment is broadly positive, with a consensus “Buy” rating and a $63.40 average price target; however, one analyst maintains a sell rating.
• Company insiders sold approximately $5.15 million of stock over the past 90 days, while institutional investors—including Frazier Life Sciences, BlackRock and ARCH Venture Management—built significant positions.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s stock price traded up 4.7% during mid-day trading on Monday. The company traded as high as $28.15 and last traded at $28.3770. 177,749 shares changed hands during trading, a decline of 73% from the average session volume of 664,715 shares. The stock had previously closed at $27.11.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. BTIG Research restated a "buy" rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Tuesday, September 22nd. Wedbush reaffirmed an "outperform" rating and set a $48.00 price target on shares of Maze Therapeutics in a report on Wednesday, September 23rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Monday, September 21st. Citigroup assumed coverage on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. They issued a "buy" rating and a $50.00 price target for the company. Finally, TD Cowen raised shares of Maze Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Maze Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $63.40.

Maze Therapeutics Stock Performance

The firm has a market capitalization of $1.59 billion, a PE ratio of -11.32 and a beta of 2.16. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The business's fifty day simple moving average is $26.85 and its 200-day simple moving average is $27.26.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting the consensus estimate of ($0.76). As a group, equities research analysts expect that Maze Therapeutics, Inc. will post -2.70 EPS for the current year.

Insider Activity at Maze Therapeutics

In other Maze Therapeutics news, CEO Jason V. Coloma sold 34,501 shares of the business's stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $26.29, for a total value of $907,031.29. Following the sale, the chief executive officer owned 18,151 shares in the company, valued at $477,189.79. The trade was a 65.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $27.58, for a total transaction of $206,850.00. Following the transaction, the insider directly owned 26,250 shares of the company's stock, valued at $723,975. This trade represents a 22.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 192,991 shares of company stock valued at $5,152,084. Corporate insiders own 5.30% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in MAZE. Frazier Life Sciences Management L.P. lifted its holdings in shares of Maze Therapeutics by 10.2% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company's stock valued at $150,182,000 after acquiring an additional 465,641 shares during the last quarter. TRV GP IV LLC purchased a new position in Maze Therapeutics in the second quarter worth about $133,502,907. ARCH Venture Management LLC bought a new stake in Maze Therapeutics during the second quarter worth approximately $122,983,582. BlackRock Inc. bought a new stake in Maze Therapeutics during the second quarter worth approximately $104,525,000. Finally, Jupiter Topco LLC bought a new stake in Maze Therapeutics during the second quarter worth approximately $101,764,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze's pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.